Arkin Bio Ventures focuses on investing in advanced pre-clinical and early clinical-stage biotechnology companies developing therapies for high unmet medical needs, particularly in oncology, immunology, inflammation, and rare diseases. Their strategy involves providing hands-on drug development support and scientific diligence to help companies achieve critical value inflection points.
67% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (67% of deals). Average disclosed round size is $56.9M (across 3 rounds with reported amounts).
Portfolio
3
Fund Size
$2B
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
3 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| RReunion Neuroscience Inc. | Series A | $103M | May 2024 |
 Auron Therapeutics | Series A | $48M | Jul 2022 |
| PPi Therapeutics | Series B | $19.7M | May 2019 |
Top Co-Investors
MPM BioImpact1 shared
Novo Holdings1 shared
Plaisance Capital Management1 shared
Palo Santo1 shared
DCVC1 shared
Mubadala Ventures1 shared
Apollo Health Ventures1 shared
Polaris Venture Partners1 shared
Qiming Venture Partners USA1 shared
Eli Lilly and Company1 shared
BrightEdge1 shared
Casdin Capital1 shared
Pontifax1 shared
Last updated: 12 April 2026